Kidney Week

Abstract: SA-PO345

Effect of Renal Denervation on Plasma Renalase Concentration in Patients with Resistant Hypertension

Session Information

• Hypertension, CVD, and the Kidneys: Clinical Research
  October 26, 2024 | Location: Exhibit Hall, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Hypertension and CVD

• 1602 Hypertension and CVD: Clinical

Authors

• Adamczak, Marcin, Department of Nephrology, Transplantation and Internal Medicine, Medical University of Silesia, Katowice, Poland

Marcin Adamczak, MD, PhD

• Czerwienska, Beata, Department of Nephrology, Transplantation and Internal Medicine, Medical University of Silesia, Katowice, Poland

Beata Czerwienska, MD

• Lelek, Michal, 1st Department of Cardiology, Medical University of Silesia, Katowice, Poland

Michal Lelek, MD

• Gojowy, Damian, Department of Nephrology, Transplantation and Internal Medicine, Medical University of Silesia, Katowice, Poland

Damian Gojowy

• Mizia-Stec, Katarzyna, 1st Department of Cardiology, Medical University of Silesia, Katowice, Poland

Katarzyna Mizia-Stec, PhD

• Wiecek, Andrzej, Department of Nephrology, Transplantation and Internal Medicine, Medical University of Silesia, Katowice, Poland

Andrzej Wiecek, MD, PhD, FASN

Background

Renalase is an enzyme produced among others by proximal tubule cells in the kidneys and participates in the degradation of catecholamine. Results of experimental studies shown that renalase secretion is stimulated by increased plasma catecholamine concentration and to some extent also by an increase in blood pressure. Renal denervation (RDN), i.e., percutaneous ablation of the sympathetic nervous system fibers located in the wall of renal arteries by radio frequency waves, is a method of patients with resistant hypertension. This single-center, interventional clinical study aimed to assess the effect of RDN on the plasma renalase concentration in patients with resistant arterial hypertension.

Methods

Twenty-five patients (12 women, 13 men) aged 54.4 ± 8.1 years with resistant hypertension who underwent renal denervation using Simplicity catheters (Medtronic, Inc., Northridge, CA) were enrolled in the study. Plasma renalase concentration was determined by enzyme-linked immunosorbent assay method (Cloud-Clone Corp., Houston, TX, USA) before RDN, 6 and 12 months after RDN. Results were presented as a mean with standard deviation.

Results

Systolic, diastolic blood pressure and heart rate were reduced after RDN (before RDN, 6 and 12 months after RDN, respectively: 190.4 ± 25.0, 161.1 ± 14.7, 155.5 ± 18.3; p<0.001; and 111.8 ± 19.3, 88.9 ± 8.5, 91.0 ± 10.4 mmHg; p<0.001 and 80.1 ± 16.3, 74.5 ± 11.1, 73.6 ± vs. 11.3 beats/min; p<0.001). Plasma renalase concentrations measured before RDN, 6 and 12 months after RDN in the studied group were 25.1 ± 7.5, 22.0 ± 7.1, and 23.1 ± 6.0 [µg/mL], respectively (ANOVA p<0.001, Fisher post hoc: before vs. six months p = 0.01, before vs. 12 months p = 0.09, six months vs. 12 months p = 0.3). There were no significant correlations between changes of plasma renalase concentration and decrease of blood pressure and heart rate during the follow-up after RDN.

Conclusion

1. Renal denervation decreases moderately plasma renalase concentration, however this effect of RDN seems to be not associated with observed decrease of blood pressure. 2. Further studies are required to evaluate whether decrease in plasma renalase concentration is associated with change in plasma catecholamine concentration.

Funding

• Government Support – Non-U.S.